Lipidor AB has announced the enrollment of the first patient in its Phase III clinical study of AKP02G2, a novel topical treatment for mild to moderate psoriasis. The trial aims to evaluate the efficacy and safety of AKP02G2, a combination of calcipotriol and betamethasone formulated using Lipidor's patented AKVANO technology.
The primary objective of AKP02G2 is to offer a patient-friendly, fast-drying spray that provides equivalent therapeutic effects to the market-leading topical treatment, Enstilar. Psoriasis, a chronic autoimmune disease, affects approximately 2-3% of the global population, presenting a significant need for effective and convenient treatment options.
The Phase III study is being conducted by Cliantha, a Clinical Research Organisation (CRO), in collaboration with Lipidor. The study plans to enroll 294 patients. "The work has resulted in the first of the 294 patients being included in the study," the company stated in a press release.
AKP02G2's formulation leverages the AKVANO technology to enhance drug delivery and improve the patient experience. The combination of calcipotriol, a vitamin D analogue, and betamethasone, a corticosteroid, is a well-established approach in psoriasis treatment, targeting both inflammation and abnormal skin cell growth. The spray formulation aims to improve adherence by offering a more convenient and less messy application compared to traditional creams and ointments.
